SOUTH
SAN FRANCISCO, Calif., Sept. 22,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq:IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced that the company plans to issue a pre-market press
release and conduct an investor webcast on Monday, September
23, 2024, at 8:00 a.m. ET to report
interim Phase 2 data for darovasertib and provide a regulatory
update from FDA Type C meeting in neoadjuvant uveal melanoma (UM).
Darovasertib is a potent and selective protein kinase C (PKC)
inhibitor being developed to broadly address primary and metastatic
UM.
The investor webcast presentation agenda to review the interim
Phase 2 clinical data and regulatory update for darovasertib in
neoadjuvant UM will be the following:
- Market introduction: annual incidence of UM
- Registrational trial design based on FDA Type C meeting
guidance
- Phase 2 clinical data update
- Baseline characteristics
- AE profile
- Clinical efficacy from Phase 2 company-sponsored
and IST
The investor webcast and conference call will include
participation from a key opinion leader. IDEAYA management,
Yujiro S. Hata, Chief Executive
Officer and President of IDEAYA Biosciences, and Darrin Beaupre, M.D., Ph.D., Chief Medical
Officer of IDEAYA Biosciences, will also serve as presenters. The
link to the investor webcast will be available on the Investor
Relations Events section of the Company's website at:
https://ir.ideayabio.com/events. Registration is available at
https://ir.ideayabio.com/events or
https://lifescievents.com/event/ideaya-3/ in advance of the
event.
IDEAYA's darovasertib investor webcast presentation, as well as
an updated corporate presentation, which will incorporate the
updated darovasertib clinical data and regulatory update, will be
available on the company's website, at its Investor Relations
portal (https://ir.ideayabio.com/) at approximately 8:00 am ET on
Monday, September 23, 2024.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) the timing and content of the
darovasertib clinical data update press release, investor
webcast and investor presentations, (ii) the timing of FDA
regulatory guidance and (iii) the timing of clinical trials
evaluating darovasertib as a treatment for primary and metastatic
UM. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. Such forward-looking statements involve
substantial risks and uncertainties. For a further description of
the risks and uncertainties that could cause actual events and
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's Annual Report on Form 10-K filed on
February 20, 2024 and any current and
periodic reports filed with the U.S. Securities and Exchange
Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-webcast-to-report-interim-phase-2-data-for-darovasertib-and-regulatory-update-from-fda-type-c-meeting-in-neoadjuvant-uveal-melanoma-on-monday-september-23-2024-302254608.html
SOURCE IDEAYA Biosciences, Inc.